CompanyDrug

Bio-Thera Wins NMPA Approval for BAT8008 BAT1006 Trastuzumab Combo Trial – Dual HER2 Trop2 Targeting in Advanced Solid Tumors

Fineline Cube
By
Fineline Cube
3 Min Read
Summarize with AI

Bio-Thera Solutions Ltd (SHA: 688177) announced NMPA clearance to initiate a clinical study evaluating BAT8008 (anti-Trop2 ADC) combined with BAT1006 (anti-HER2 antibody) plus trastuzumab in HER2-positive advanced solid tumors. The triplet regimen represents a novel dual-HER2/Trop2 targeting strategy leveraging Bio-Thera’s proprietary ADC platform and bispecific-like antibody engineering to address tumor heterogeneity in refractory cancers.

Contents
- Advertisement -

Regulatory Milestone

ItemDetail
AgencyNMPA (China)
Approval TypeClinical trial authorization (IND)
Study DesignBAT8008 + BAT1006 + trastuzumab combination
IndicationHER2-positive advanced solid tumors
DeveloperBio-Thera Solutions Ltd (SHA: 688177)
Approval DateMarch 2026

Product Profiles & Mechanism

BAT8008 (Anti-Trop2 ADC)

AttributeSpecification
StructureRecombinant humanized anti-Trop2 antibody + topoisomerase I inhibitor payload
LinkerSelf-developed cleavable linker
MechanismTargeted delivery of cytotoxic payload to Trop2-expressing tumor cells
Key FeatureStrong bystander effect – toxin diffusion kills neighboring antigen-negative cells, overcoming tumor heterogeneity
ActivityEfficient anti-tumor activity in preclinical models

BAT1006 (Anti-HER2 Antibody)

AttributeSpecification
TargetHER2 extracellular dimerization domain (Subdomain II)
MechanismBlocks ligand-dependent HER2 heterodimerization with EGFR, HER3, HER4
Downstream EffectInhibition of MAP kinase and PI3K signaling pathways
OutcomeCell growth arrest and apoptosis
DifferentiationNovel epitope targeting vs. trastuzumab (Subdomain IV)

Trastuzumab (Herceptin)

| Role | Established anti-HER2 backbone; Fc-mediated immune effector functions |

Combination Rationale & Strategic Value

ComponentContribution to Triplet
TrastuzumabHER2 signaling blockade (Subdomain IV) + ADCC-mediated tumor killing
BAT1006Complementary HER2 dimerization blockade (Subdomain II); broader HER family inhibition
BAT8008Trop2-directed cytotoxic payload; bystander effect addresses HER2-negative tumor clones

Scientific Synergy:

  • Dual HER2 blockade: Trastuzumab + BAT1006 target distinct epitopes → comprehensive HER2 pathway shutdown
  • Dual antigen targeting: HER2 + Trop2 co-expression in many solid tumors (breast, gastric, urothelial)
  • Heterogeneity solution: Bystander effect from BAT8008 payload addresses antigen-loss variants

Competitive Context

FactorMarket Implication
ADC LandscapeTrop2 ADCs (sacituzumab govitecan, datopotamab deruxtecan) approved; BAT8008 differentiated by proprietary linker/payload
HER2 InnovationBAT1006’s Subdomain II binding offers mechanism complementary to established antibodies
Combination TrendADC + immune checkpoint or targeted therapy combinations gaining traction; triplet with dual HER2 blockade novel
China PositioningBio-Thera advances domestic ADC innovation; potential for global partnership on differentiated platform

Development Outlook

  • Phase I Design: Dose-escalation of triplet combination; biomarker-enriched HER2-positive solid tumor cohorts
  • Expansion Cohorts: Breast cancer, gastric cancer, urothelial carcinoma prioritized based on HER2/Trop2 co-expression
  • Manufacturing: Bio-Thera’s integrated ADC facility supports clinical and commercial supply
  • Global Strategy: China-first development; U.S./EU IND filing contingent on Phase I safety/efficacy data

Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical development timelines, combination efficacy, and partnership potential for Bio-Thera’s BAT8008 and BAT1006 programs. Actual results may differ due to trial outcomes, competitive dynamics, and manufacturing complexities.-Fineline Info & Tech

688177_20260307_4A07Download
TAGGED:
Share This Article
Previous Article Novo Nordisk's IcoSema Wins NMPA Approval – Once-Weekly Insulin-Semaglutide Combo Targets China Type 2 Diabetes Market Novo Nordisk’s IcoSema Wins NMPA Approval – Once-Weekly Insulin-Semaglutide Combo Targets China Type 2 Diabetes Market
Next Article Dongcheng Pharma Doses First Patient in 225Ac-LNC1011 Phase I/II Trial – PSMA-Targeted Alpha Radiotherapy for Metastatic Prostate Cancer

You May also Like

CompanyDeals

Suzhou Acumen Biomedical Secures $13.8 Million in Series A+ Funding Round

CompanyDeals

Sichuan Biokin and Bristol-Myers Squibb Activate $800 Million ADC Licensing Deal

Company

Kelun Pharmaceutical Receives USD 30 Million from MSD for Licensing Deal

Akeso’s ivonescimab (AK112) Receives Fourth Breakthrough Therapy Designation in China for Triple‑Negative Breast Cancer
CompanyDrug

Akeso’s ivonescimab (AK112) Receives Fourth Breakthrough Therapy Designation in China for Triple‑Negative Breast Cancer

Show More